Stay updated on Atezolizumab and Entinostat in aTN Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab and Entinostat in aTN Breast Cancer Clinical Trial page.

Latest updates to the Atezolizumab and Entinostat in aTN Breast Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedA revision note for v3.4.2 was added and the previous revision note v3.4.1 was removed.SummaryDifference0.0%

- Check19 days agoChange DetectedSite revision updated from v3.4.0 to v3.4.1; no changes to the study details or visible content.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision history updated from v3.3.3 to v3.3.4; no substantive changes to the study details or eligibility criteria are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check62 days agoChange DetectedAdded a consolidated Locations section listing participating sites across Alabama, California, Colorado, Florida, Indiana, Kansas, Minnesota, New Jersey, North Carolina, Texas, Adjara, and Imereti. This replaces the prior separate location blocks and centralizes site information for potential participants.SummaryDifference1%

- Check91 days agoChange DetectedRevision: v3.3.2 is displayed in the page metadata, replacing v3.2.0, and this internal update does not modify study content, eligibility criteria, or locations; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check99 days agoChange DetectedThe page no longer displays the government funding status notice; core trial information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Atezolizumab and Entinostat in aTN Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab and Entinostat in aTN Breast Cancer Clinical Trial page.